Clinical and Immunologic Outcomes After Immediate or Deferred Antiretroviral Therapy Initiation During Primary Human Immunodeficiency Virus Infection: The Sabes Randomized Clinical Study | Zendy

Javier R. Lama | Zendy; Rachel Bender Ignacio | Zendy; Ricardo Alfaro | Zendy; Jessica Ríos | Zendy; Jorge A Gallardo-Cartagena | Zendy; Rogelio Valdez | Zendy; Carolyn Bain | Zendy; Karin Sosa Barbarán | Zendy; Manuel Villarán | Zendy; Christopher D. Pilcher | Zendy; Pedro Gonzáles | Zendy; Jorge Sánchez | Zendy; Ann Duerr | Zendy

Open Access

Clinical and Immunologic Outcomes After Immediate or Deferred Antiretroviral Therapy Initiation During Primary Human Immunodeficiency Virus Infection: The Sabes Randomized Clinical Study

Author(s) -

Javier R. Lama,

Rachel Bender Ignacio,

Ricardo Alfaro,

Jessica Ríos,

Jorge A Gallardo-Cartagena,

Rogelio Valdez,

Carolyn Bain,

Karin Sosa Barbarán,

Manuel Villarán,

Christopher D. Pilcher,

Pedro Gonzáles,

Jorge Sánchez,

Ann Duerr

Publication year - 2020

Publication title -

clinical infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.44

H-Index - 336

eISSN - 1537-6591

pISSN - 1058-4838

DOI - 10.1093/cid/ciaa167

Subject(s) - medicine , human immunodeficiency virus (hiv) , antiretroviral therapy , sida , randomized controlled trial , immunology , clinical trial , virology , intensive care medicine , viral disease , viral load

In addition to demonstrated public health benefits on reducing transmission, it remains unclear how early antiretroviral therapy (ART) must be started after acquisition of human immunodeficiency virus (HIV) to maximize individual benefits.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research